Atogepant Under Review for Episodic Migraine Prevention
Atogepant is an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist.
Migraine and Headache
Drug Combo Superior to Placebo for Posttraumatic Headache
Pain relief greater with IV metoclopramide + diphenhydramine administered in the ED, but more adverse events reported
FDA Clears Wearable Brain Neuromodulation Device for Acute Migraine
Relivion is worn as a headset delivering stimulation to 6 branches of the occipital and trigeminal nerves through 3 adaptive output channels.
MPR Weekly Dose Podcast 69
An FDA warning to pharma company regarding their promo material; Entresto’s approval is expanded; There’s approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropathy; And a migraine device is OK’d for teens.
FDA Clears Vagus Nerve Stimulation Device for Adolescent Migraine
Findings from an adolescent study showed that 46.8% of treated attacks were successfully resolved without the use of any acute rescue medication.
Headache May Be an Early, Isolated Feature of COVID-19
Headache may be an early symptom of COVID-19, and identifying patients with characteristic features may help provide early isolation and treatment.
Nerivio Device Cleared for Migraine in Adolescents
The approval was based on data from an open-label, single-arm study that evaluated the efficacy and safety of Nerivio in patients aged 12 to 17 years with migraine.
Novel Intranasal DHE Under Review for Migraine
INP104 uses proprietary technology to deliver a lower dose (1.45mg) of dihydroergotamine mesylate (DHE) to the upper nasal space.
New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
NDA Submitted for Novel Intranasal DHE for Migraine
INP104 uses proprietary technology to deliver a lower dose (1.45mg) of dihydroergotamine mesylate (DHE) to the upper nasal space.
